Synopsis
Synopsis
0
VMF
0
Australia
Annual Reports
NA
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. (e)-n-(6,6-dimethyl-2-heptenynyl)-n-methyl-1-naphthalenementhamin Hydrochloride
2. Da 5505
3. Lamisil
4. Sf 86 327
5. Sf 86-327
6. Sf 86327
7. Sf-86-327
8. Sf86327
9. Tdt 067
10. Tdt-067
11. Tdt067
12. Terbinafine
13. Terbinafine, (z)-
14. Terbinafine, (z)-isomer
1. Terbinafine Hcl
2. 78628-80-5
3. Lamisil At
4. (e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine Hydrochloride
5. Bramazil
6. Bramizil
7. Muzonal
8. Terbina
9. Terbine
10. Terbinafina
11. Terbinafinum
12. Zabel
13. Nsc-759113
14. Cpd000469152
15. Terbinafine (as Hydrochloride)
16. Chebi:77614
17. 012c11zu6g
18. (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethylamine Hydrochloride
19. Trans-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthylmethylamine Hydrochloride
20. 78628-80-5 (hcl)
21. Lamisil Krem
22. Trans-n-(6,6-dimethyl-2-hepten-4-ylyl)-n-methyl-1-naphthylmethylamine Hydrochloride
23. Terbinafinum [latin]
24. Terbinafina [spanish]
25. Athletes Foot
26. Mycova
27. (e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine;hydrochloride
28. [(2e)-6,6-dimethylhept-2-en-4-yn-1-yl](methyl)(naphthalen-1-ylmethyl)amine Hydrochloride
29. N-[(2e)-6,6-dimethyl-2-hepten-4-yn-1-yl]-n-methyl-1-naphthalenemethanamine Hydrochloride
30. Sf 86-327 Hydrochloride
31. Smr000469152
32. N,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-amine Hydrochloride
33. Drg-0286
34. Terbinafine (hydrochloride)
35. Terbisil
36. Afogan
37. Terbifoam
38. Innonyx
39. Unii-012c11zu6g
40. Lamisil (tn)
41. Terbinafine Hydrochloride [usp:jan]
42. Mfcd00145430
43. Terbinafine,hydrochloride
44. Ec 616-640-4
45. Terbinafine Monohydrochloride
46. Schembl36793
47. Schembl36795
48. Mls001066620
49. Mls001304037
50. Mls001401424
51. Terbinafine Hydrochloride,(s)
52. Chembl1200832
53. Dtxsid90229223
54. Htu-520
55. Pharmakon1600-01505392
56. Terbinafine Hydrochloride, >=98%
57. Terbinafine Hydrochloride (lamisil)
58. Ac-761
59. Nsc759113
60. S2557
61. Terbinafine Hydrochloride [mi]
62. Akos015844100
63. Akos025149216
64. Terbinafine Hydrochloride (jp17/usp)
65. Bcp9000834
66. Ccg-101026
67. Cs-1123
68. Ks-1289
69. Nc00276
70. Nsc 759113
71. Terbinafine Hydrochloride [jan]
72. Terbinafine Hydrochloride [mart.]
73. Terbinafine Hydrochloride [vandf]
74. 1-naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-, (e)-, Monohydrochloride
75. 1-naphthalenemethanamine, N-[(2e)-6,6-dimethyl-2-hepten-4-yn-1-yl]-n-methyl-, Hydrochloride (1:1)
76. Bt164461
77. Hy-17395
78. Ls-14899
79. Sf-86327
80. Terbinafine Hydrochloride [usp-rs]
81. Terbinafine Hydrochloride [who-dd]
82. Nm-100060
83. B2047
84. D2049
85. Sw197656-2
86. D02219
87. Terbinafine Hydrochloride [ep Monograph]
88. Terbinafine Hydrochloride [orange Book]
89. Terbinafine Hydrochloride [usp Monograph]
90. 628t805
91. A839463
92. Q-201790
93. Q27147212
94. Terbinafine Hydrochloride, Antibiotic For Culture Media Use Only
95. Terbinafine Hydrochloride, European Pharmacopoeia (ep) Reference Standard
96. (2e)-n,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-amine Hydrochloride
97. (2e)-n,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-amine Hydrochloride (1:1)
98. (2e)-n,6,6-trimethyl-n-(1-naphthylmethyl)hept-2-en-4-yn-1-aminium Chloride
99. (2e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-amine Hydrochloride
100. (e)-n,6,6-trimethyl-n-(naphthalen-1-ylmethyl)hept-2-en-4-yn-1-aminehydrochloride
101. (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethanamine Hydrochloride
102. (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthylmethylamine Hydrochloride
103. [(e)-6,6-dimethylhept-2-en-4-ynyl]-methyl-(naphthalen-1-ylmethyl)azanium;chloride
104. Terbinafine For System Suitability, European Pharmacopoeia (ep) Reference Standard
105. Terbinafine Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
106. Terbinafine Hydrochloride, United States Pharmacopeia (usp) Reference Standard
107. (e)-n-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-1-naphthalenemethylamine, Hydrochloride
108. 1-naphthalenemethanamine, N-(6,6-dimethyl-2-hepten-4-ynyl)-n-methyl-, (e)-, Hydrochloride
Molecular Weight | 327.9 g/mol |
---|---|
Molecular Formula | C21H26ClN |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 1 |
Rotatable Bond Count | 5 |
Exact Mass | 327.1753775 g/mol |
Monoisotopic Mass | 327.1753775 g/mol |
Topological Polar Surface Area | 3.2 Ų |
Heavy Atom Count | 23 |
Formal Charge | 0 |
Complexity | 428 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 1 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 6 | |
---|---|
Drug Name | Lamisil |
Drug Label | Lamisil Tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. The empirical formula C21H26... |
Active Ingredient | Terbinafine hydrochloride |
Dosage Form | Tablet; Cream; Granule |
Route | Oral; Topical |
Strength | eq 187.5mg base/packet; 1%; eq 250mg base; eq 125mg base/packet |
Market Status | Over the Counter; Prescription |
Company | Novartis |
2 of 6 | |
---|---|
Drug Name | Lamisil at |
Active Ingredient | Terbinafine hydrochloride; Terbinafine |
Dosage Form | Spray; Gel; Solution |
Route | Topical |
Strength | 1% |
Market Status | Over the Counter |
Company | Novartis |
3 of 6 | |
---|---|
Drug Name | Terbinafine hydrochloride |
PubMed Health | Terbinafine |
Drug Classes | Antifungal |
Drug Label | Terbinafine hydrochloride tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. The empiri... |
Active Ingredient | Terbinafine hydrochloride |
Dosage Form | Tablet; Cream |
Route | oral; Oral; Topical |
Strength | 1%; eq 250mg base |
Market Status | Tentative Approval; Over the Counter; Prescription |
Company | Wockhardt; Harris Pharm; Breckenridge Pharm; Teva; Apotex; Aurobindo Pharma; Taro; Andrx Pharm; Invagen Pharms; Cipla; Glenmark Generics; Dr Reddys Labs; Orchid Hlthcare; Mylan |
4 of 6 | |
---|---|
Drug Name | Lamisil |
Drug Label | Lamisil Tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. The empirical formula C21H26... |
Active Ingredient | Terbinafine hydrochloride |
Dosage Form | Tablet; Cream; Granule |
Route | Oral; Topical |
Strength | eq 187.5mg base/packet; 1%; eq 250mg base; eq 125mg base/packet |
Market Status | Over the Counter; Prescription |
Company | Novartis |
5 of 6 | |
---|---|
Drug Name | Lamisil at |
Active Ingredient | Terbinafine hydrochloride; Terbinafine |
Dosage Form | Spray; Gel; Solution |
Route | Topical |
Strength | 1% |
Market Status | Over the Counter |
Company | Novartis |
6 of 6 | |
---|---|
Drug Name | Terbinafine hydrochloride |
PubMed Health | Terbinafine |
Drug Classes | Antifungal |
Drug Label | Terbinafine hydrochloride tablets contain the synthetic allylamine antifungal compound terbinafine hydrochloride.Chemically, terbinafine hydrochloride is (E)-N-(6,6-dimethyl-2-hepten-4-ynyl)-N-methyl-1-naphthalenemethanamine hydrochloride. The empiri... |
Active Ingredient | Terbinafine hydrochloride |
Dosage Form | Tablet; Cream |
Route | oral; Oral; Topical |
Strength | 1%; eq 250mg base |
Market Status | Tentative Approval; Over the Counter; Prescription |
Company | Wockhardt; Harris Pharm; Breckenridge Pharm; Teva; Apotex; Aurobindo Pharma; Taro; Andrx Pharm; Invagen Pharms; Cipla; Glenmark Generics; Dr Reddys Labs; Orchid Hlthcare; Mylan |
Treatment of onychomycosis
Antifungal Agents
Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. (See all compounds classified as Antifungal Agents.)
Enzyme Inhibitors
Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.
About the Company : Established in 2004, Metrochem API is one of the fastest-growing APIs, pellets & intermediates manufacturers. It has 6 dedicated manufacturing facilities for its 3 core product gro...
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
About the Company : Founded in 1984, DRL is well-known for its generic APIs and its track record in drug product development. It is one of the earliest pharma API manufacturers with a diverse portfoli...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
China's leading API and intermediate manufacturer, offering CMO/CDMO services and exports to 70+ countries, enhancing global health.
About the Company : Shandong Chenghui Shuangda Pharmaceutical Co., Ltd. is specialized in R&D and production of APIs and advanced intermediates. With 22 years of production experience,the company has ...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Tagoor's product development expertise, backed by our comprehensive understanding of the processes, helps us offer high-quality APIs.
About the Company : Tagoor Laboratories, established in 2018, is a part of the Tagoor Group. It specializes in providing APIs, advanced intermediates and key starting materials for critical and high-g...
About the Company : Founded in 1986 by Mr. P.V. Ramaprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born off a vision. The company comme...
About the Company : Chr. Olesen Synthesis is a Danish manufacturer of APIs and advanced intermediates. Chr. Olesen Synthesis was established in 2012 after the Chr. Olesen Group acquisition of the mult...
About the Company : Hy-Gro Chemicals Pharmtek Pvt. Ltd. (Hy-Gro) is a fast growing pharmaceutical company engaged in the manufacture of Active Pharmaceutical Ingredients (APIs), Advanced Intermediates...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
98
PharmaCompass offers a list of Terbinafine Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Terbinafine Hydrochloride manufacturer or Terbinafine Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Terbinafine Hydrochloride manufacturer or Terbinafine Hydrochloride supplier.
PharmaCompass also assists you with knowing the Terbinafine Hydrochloride API Price utilized in the formulation of products. Terbinafine Hydrochloride API Price is not always fixed or binding as the Terbinafine Hydrochloride Price is obtained through a variety of data sources. The Terbinafine Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A ACN-S001257 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of ACN-S001257, including repackagers and relabelers. The FDA regulates ACN-S001257 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. ACN-S001257 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of ACN-S001257 manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A ACN-S001257 supplier is an individual or a company that provides ACN-S001257 active pharmaceutical ingredient (API) or ACN-S001257 finished formulations upon request. The ACN-S001257 suppliers may include ACN-S001257 API manufacturers, exporters, distributors and traders.
click here to find a list of ACN-S001257 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A ACN-S001257 DMF (Drug Master File) is a document detailing the whole manufacturing process of ACN-S001257 active pharmaceutical ingredient (API) in detail. Different forms of ACN-S001257 DMFs exist exist since differing nations have different regulations, such as ACN-S001257 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A ACN-S001257 DMF submitted to regulatory agencies in the US is known as a USDMF. ACN-S001257 USDMF includes data on ACN-S001257's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The ACN-S001257 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of ACN-S001257 suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The ACN-S001257 Drug Master File in Japan (ACN-S001257 JDMF) empowers ACN-S001257 API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the ACN-S001257 JDMF during the approval evaluation for pharmaceutical products. At the time of ACN-S001257 JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of ACN-S001257 suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a ACN-S001257 Drug Master File in Korea (ACN-S001257 KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of ACN-S001257. The MFDS reviews the ACN-S001257 KDMF as part of the drug registration process and uses the information provided in the ACN-S001257 KDMF to evaluate the safety and efficacy of the drug.
After submitting a ACN-S001257 KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their ACN-S001257 API can apply through the Korea Drug Master File (KDMF).
click here to find a list of ACN-S001257 suppliers with KDMF on PharmaCompass.
A ACN-S001257 CEP of the European Pharmacopoeia monograph is often referred to as a ACN-S001257 Certificate of Suitability (COS). The purpose of a ACN-S001257 CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of ACN-S001257 EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of ACN-S001257 to their clients by showing that a ACN-S001257 CEP has been issued for it. The manufacturer submits a ACN-S001257 CEP (COS) as part of the market authorization procedure, and it takes on the role of a ACN-S001257 CEP holder for the record. Additionally, the data presented in the ACN-S001257 CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the ACN-S001257 DMF.
A ACN-S001257 CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. ACN-S001257 CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of ACN-S001257 suppliers with CEP (COS) on PharmaCompass.
A ACN-S001257 written confirmation (ACN-S001257 WC) is an official document issued by a regulatory agency to a ACN-S001257 manufacturer, verifying that the manufacturing facility of a ACN-S001257 active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting ACN-S001257 APIs or ACN-S001257 finished pharmaceutical products to another nation, regulatory agencies frequently require a ACN-S001257 WC (written confirmation) as part of the regulatory process.
click here to find a list of ACN-S001257 suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing ACN-S001257 as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for ACN-S001257 API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture ACN-S001257 as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain ACN-S001257 and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a ACN-S001257 NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of ACN-S001257 suppliers with NDC on PharmaCompass.
ACN-S001257 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of ACN-S001257 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right ACN-S001257 GMP manufacturer or ACN-S001257 GMP API supplier for your needs.
A ACN-S001257 CoA (Certificate of Analysis) is a formal document that attests to ACN-S001257's compliance with ACN-S001257 specifications and serves as a tool for batch-level quality control.
ACN-S001257 CoA mostly includes findings from lab analyses of a specific batch. For each ACN-S001257 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
ACN-S001257 may be tested according to a variety of international standards, such as European Pharmacopoeia (ACN-S001257 EP), ACN-S001257 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (ACN-S001257 USP).